

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
11373

In Re Application Of: Tracy Willson, et al.



Serial No.
09/051,843

Filing Date
October 23, 1996 (Int'l.)

Examiner

Group Art Unit
1801

Title: **A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME**

RECEIVED

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

NOV 16 1998

GROUP 1800

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
 2. a Notice of Allowance under 37 CFR 1.311,
- whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);


OR

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(e))

Docket No.
11373

In Re Application Of: Tracy Willson, et al.



Serial No.
09/051,843

Filing Date
October 23, 1996 (Int'l.)

Examiner

Group Art Unit
1801

Title: A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____) on _____ (Date)

Signature

Typed or Printed Name of Person Signing Certificate

*This certificate may only be used if paying by deposit account.

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on November 13, 1998 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Frank S. DiGiglio

Typed or Printed Name of Person Mailing Correspondence

Signature

Dated: November 13, 1998

Frank S. DiGiglio
Registration No. 31,346

SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, NY 11530
(516) 742-4343

CC:



#17

PATENTS .

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Tracy Willson, et al.

Art Unit: 1801

Serial No.: 09/051,843

Docket: 11373

International

Application No.: PCT/AU96/00668

Dated: November 13, 1998

International

Filing Date: October 23, 1996

For: A NOVEL HAEMOPOIETIN RECEPTOR
AND GENETIC SEQUENCES ENCODING
SAME

Assistant Commissioner for Patents
Washington, DC 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:


In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following disclosures, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

Hilton, et al. (January 1996) "Cloning and Characterization of a Binding Subunit of the Interleukin 13 Receptor that is also a Component of the Interleukin 4 Receptor", Proc. Natl. Acad. Sci. USA 93:497-501.

Matthews, et al. (January 1, 1995) "Function of the Interleukin-2 (IL-2) Receptor γ -Chain in Biologic

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on November 13, 1998.

Dated: November 13, 1998
Frank S. DiGiglio

Responses, of X-Linked Severe Combined Immunodeficient B Cells to IL-2, IL-4, IL-13 and IL-15", Blood 85(1):38-42.

Miloux, et al. (1997) "Cloning of the Human IL-13R α 1 Chain and Reconstitution with the IL-4R α of a Functional IL-4/IL-13 Receptor Complex", FEBS Letters 401:163-166.

Obiri, et al. (April 14, 1995) "Receptor for Interleukin 18: Interaction with Interleukin 4 by a Mechanism that does not Involve the Common γ Chain Shared by Receptors for Interleukins 2, 4, 7, 9 and 15", The Journal of Biological Chemistry 270(16):8797-8804.

Obiri, et al. "The IL-13 Receptor Structure Differs on Various Cell Types and may Share More than One Component with IL-4 Receptor", The Journal of Immunology:756-764.

Smerz-Bertling, et al. (January 13, 1995) "Both Interleukin 4 and Interleukin 13 Induce Tyrosine Phosphorylation of the 140-kDa Subunit of the Interleukin 4 Receptor", The Journal of Biological Chemistry 270(2):966-970.

Vita, et al. (February 24, 1995) "Characterization and Comparison of the Interleukin 13 Receptor with the Interleukin 4 Receptor on Several Cell Types", The Journal of Biological Chemistry 270(8):3512-3517.

Zhang, et al. (April 4, 1997) "Identification, Purification and Characterization of a Soluble Interleukin (IL)-13-Binding Protein", The Journal of Biological Chemistry 272(14):9474-9480.

Zurawski, et al. (1993) "Receptors for Interleukin-13 and Interleukin-4 are Complex and Share a Novel Component that Functions in Signal Transduction", The EMBO Journal 12(7):2663-2670.


Zurawski, et al. (June 9, 1995) "The Primary Binding Subunit of the Human Interleukin-4 Receptor is also a Component of the Interleukin-13 Receptor", The Journal of Biological Chemistry 270(23):13869-13878.

PCT Publication No. WO 97/20926 published June 12, 1997.

Consideration of this Supplemental Information Disclosure Statement is respectfully requested, since the information provided herewith may be material to the examination of the present application as defined under 37 C.F.R. §1.56(a).

Inasmuch as this Supplemental Information Disclosure Statement is being filed prior to the issuance of a first Official Action on the merits, no fee or certification is due.

Respectfully submitted,



Frank S. DiGiglio
Registration No. 31,346

SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343

PIB:ld